The von Hippel-Lindau tumor suppressor gene and kidney cancer
about
sameAs
RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer genePrevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort studyBroad targeting of angiogenesis for cancer prevention and therapyEvidence That Two Enzyme-derived Histidine Ligands Are Sufficient for Iron Binding and Catalysis by Factor Inhibiting HIF (FIH)Role of angiogenesis in urothelial bladder carcinomamicroRNAs in kidneys: biogenesis, regulation, and pathophysiological rolesHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellspVHL function is essential for endothelial extracellular matrix deposition.The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth.Epigenetic regulation of thyroid hormone receptor beta in renal cancer.Role of the ubiquitin proteasome system in renal cell carcinoma.Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabCombination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near futureClinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function.The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.Changes in clinicopathological characteristics of renal cell carcinoma in the past 25 years: a single-center experience.Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitroTalactoferrin immunotherapy in metastatic renal cell carcinoma: a case series of four long-term survivors.The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinomaCharacterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevanceVHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.Causes and consequences of DNA hypomethylation in human cancer.The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis.High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profileGenotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomasAn Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control.Familial syndromes coupling with small renal masses.Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.Von Hippel-Lindau and myotonic dystrophy of Steinert along with pancreatic neuroendocrine tumor and renal clear cell carcinomal neoplasm: Case report and review of the literature.Sunitinib therapy in renal cell carcinoma.Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
P2860
Q24305480-4B86D601-7A4B-4000-A8DD-F04E80A04E10Q24813050-31EB3460-39CD-41EA-A0B2-D25F032244E0Q27002903-EE628696-6BF5-40A3-9F87-7BDF70A3C9C8Q27651089-C1DEFB6D-4415-4C61-AC85-84BB151C0AA7Q28080330-EAFF6285-2D61-4F31-930B-E4FE6DF45D51Q28387168-6354A9CA-942C-4B5A-8F94-A3D20043B981Q28393898-373D4720-A972-4EDC-9AD4-622945975B57Q28589604-5E24DC78-BA70-4747-AA69-7EB51FBAF306Q28594394-27B85DEF-278D-4D94-88D8-DBD1DA948633Q30480543-D665ACE1-4E73-4EF5-BAFE-00348D55938FQ31161553-DA132DA3-6998-492D-B6CF-AF82F1F20D48Q33307879-62ED5891-7226-4B42-ABBB-245F49B10850Q33418562-2858A9E0-D635-4866-B9E9-5FFA380DC30EQ33439523-E7602785-0D16-423D-A9D9-0AA5FEDF2F92Q33558337-7C594D5F-9489-46F6-8B65-81C2C33BF098Q33597062-FC84032A-0131-473A-8D72-AAFEB9E19B49Q33599713-90C2A18F-8CEF-4261-8168-77B39537975AQ34217763-1E2A0B02-F5E4-40D2-8A69-216EC0C8712DQ34449959-247A4C01-6548-48A3-A4E8-180EB3AD9AC8Q34569380-55945710-AC9C-46D7-84CA-888AC682F628Q34609828-D06D19D2-443A-4C82-8C64-C4239E3BDC0CQ34645498-CEA63C72-62A9-402A-8E8D-785EC0FB355FQ35356020-3EE3ED41-F2DA-40CB-A58E-E573E6A5DD52Q35464515-899B47F9-C412-4C24-B42F-EF5F18CB1540Q35574224-A0D8E666-197E-4CC7-93F2-563F9D8A0CD3Q35606411-C4087B6C-BE59-414C-8EF8-D25191897752Q36105139-0A60862A-0947-4080-B1C5-1468BEF2824EQ36127410-4C3592E6-2E55-4892-B95A-20671E041FDDQ36164751-C17C35AE-384A-4924-A19B-9544CA4B171CQ36300487-77E652E5-EF47-43AF-829C-FC295668305AQ36609613-FB40B9AD-6AAC-45EA-BF35-3E7619A895D2Q36730594-281CF1A3-5673-40A9-9F16-4971AEB84FC1Q36732789-F3227787-FE64-465E-A538-4D5389BB4275Q36768291-AFBDD4C8-AECD-4603-9B36-143F92574DCFQ36808720-A1F66B3B-A35B-41D2-8F79-2332817C6BFAQ36848153-7F57B385-C81C-4D7D-90F2-50DD358AC8C9Q37003374-03C692BB-A072-4D51-B729-9C5A2B198EB1Q37010969-CF57A3EA-9097-4E2A-99E2-7FEB436131BEQ37088460-B4E26C2D-1608-4060-B8EC-25FAFF70FE8FQ37147482-8B77F061-6E4B-47B1-8752-26073D3762FB
P2860
The von Hippel-Lindau tumor suppressor gene and kidney cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@ast
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@en
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@nl
type
label
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@ast
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@en
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@nl
altLabel
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
@en
prefLabel
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@ast
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@en
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@nl
P3181
P1476
The von Hippel-Lindau tumor suppressor gene and kidney cancer
@en
P304
6290S-6295S
P3181
P356
10.1158/1078-0432.CCR-SUP-040025
P407
P433
P577
2004-09-15T00:00:00Z